Expression of ORAOV 1 , ABCG 2 , and KiSS-1 associate with prognosis in laryngeal squamous cell carcinoma
Wenqing Song,Lei Zhou,Xiaomeng Gong,Shiwu Wu,Lan Yu,Bo Zhu,Danna Wang
2017-01-01
Abstract:Background: Oral cancer overexpressed 1 (ORAOV1, a novel candidate oncogene), ATP-binding cassette sub-family G member (ABCG2, a biomarker of cancer stem cells), and KiSS-1 (a suppressor of tumor metastasis) are all usefully predictive factors for metastasis in various cancers. However, the metastatic and prognostic value of ORAOV1, ABCG2, or KiSS-1 in laryngeal squamous cell carcinoma (LSCC) is still unclear. In this study, we analyzed correlations among ORAOV1, ABCG2, and KiSS-1 in LSCC, and their respective correlations with clinicopathological characteristics and survival in LSCC. Methods: Specimens from 130 Chinese patients with follow-up were analyzed for ORAOV1, ABCG2, and KiSS-1 protein expression by immunohistochemical staining. The Pearson Chi’s square test was used to assess the associations among of these biomarkers and clinicopathological characteristics. The overall survival was studied by univariate and multivariate analyses. Results: Levels of ORAOV1 and ABCG2 were significantly higher, and levels of KiSS-1 were significantly lower, in LSCC tissues than those in control tissues. Levels of ORAOV1 and ABCG2 were positively correlated with primary tumors (pT), lymph node metastasis (LNM), and tumornode-metastasis (TNM) stages, and negatively with patients overall survival (OS) time; levels of KiSS-1 was inversely associated with tumor grades, pT, LNM, and TNM stages, and the positive expression of KiSS-1 subgroup had significantly longer OS time than did the negative expression of KiSS-1 subgroup. In multivariate analysis, positive expression ORAOV1, ABCG2, or KiSS-1 and tumor stages, as well as TNM stages were potential to be independent prognostic factors for OS time in patients with LSCC. Conclusions: ORAOV1, ABCG2, and KiSS-1 represent promising metastatic and prognostic biomarkers, as well as potential therapeutic targets, for LSCC.